The landmark study by Reichert et al. (2001) systematically analyzed the impact of Japan’s national policy to vaccinate schoolchildren against influenza on overall and pneumonia/influenza-associated mortality, spanning...
Epidemiology Global burden: Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide, with over 200 identified HPV types, of which at least 12 are oncogenic or high-risk types. HPV causes...
Key updates for 2025-26 season Vaccine composition changes All influenza vaccines available in the United States during the 2025-26 season will be trivalent, containing hemagglutinin derived from: H1N1 component:...
Chikungunya virus disease risk in Europe is rising sharply in 2025, with locally acquired cases now confirmed in both France and Italy, and record numbers of outbreaks attributed to the spread and establishment of Aedes...
US policy shift on mRNA vaccines The US Department of Health and Human Services (HHS) announced it is winding down ~$500 million in mRNA vaccine development projects, terminating 22 government-supported BARDA...
Definition Seroprotection refers to the situation in which an individual, following vaccination or natural infection, achieves a serologically measurable antibody concentration or titer that has been designated by...
In 2025, the US government stopped recommending COVID-19 vaccines for healthy children, prompting insurers to drop coverage and leaving families with vulnerable members at risk. This abrupt change replaced the...
The article offers an in-depth examination of the sweeping and controversial changes implemented during Kennedy’s tenure as Secretary of Health and Human Services. Kennedy, a polarizing figure, has moved to wind down...
Here’s a summary of the main arguments and the authors’ conclusion from the attached editorial “SARS-CoV-2 origins: imperfect but clear evidence” from The Lancet Microbe (2025): The Lancet Microbe. SARS-CoV...
1. Pfizer (USA) and BioNTech (Germany) News: Pfizer and BioNTech have submitted a new application to the European Medicines Agency for a COVID-19 vaccine adapted to the 2025–2026 LP.8.1 strain. Pfizer and BioNTech...